Leerink Partnrs Analysts Lower Earnings Estimates for DexCom

DexCom, Inc. (NASDAQ:DXCM - Free Report) - Investment analysts at Leerink Partnrs decreased their FY2026 earnings estimates for shares of DexCom in a research note issued to investors on Thursday, October 24th. Leerink Partnrs analyst M. Kratky now anticipates that the medical device company will post earnings per share of $2.46 for the year, down from their previous forecast of $2.49. The consensus estimate for DexCom's current full-year earnings is $1.69 per share. Leerink Partnrs also issued estimates for DexCom's FY2027 earnings at $2.77 EPS and FY2028 earnings at $3.14 EPS.

DexCom (NASDAQ:DXCM - Get Free Report) last posted its earnings results on Thursday, July 25th. The medical device company reported $0.43 EPS for the quarter, topping the consensus estimate of $0.39 by $0.04. The business had revenue of $1 billion during the quarter, compared to analysts' expectations of $1.04 billion. DexCom had a return on equity of 31.41% and a net margin of 16.95%. The firm's revenue was up 15.3% on a year-over-year basis. During the same period in the previous year, the business earned $0.34 earnings per share.

Other equities analysts have also recently issued research reports about the stock. Oppenheimer reduced their price target on shares of DexCom from $115.00 to $105.00 and set an "outperform" rating on the stock in a research report on Friday. Canaccord Genuity Group reissued a "buy" rating and set a $145.00 price target on shares of DexCom in a research report on Tuesday, July 23rd. Sanford C. Bernstein boosted their target price on DexCom from $82.00 to $86.00 and gave the stock an "outperform" rating in a report on Friday. Raymond James decreased their target price on shares of DexCom from $115.00 to $99.00 and set a "strong-buy" rating for the company in a report on Friday. Finally, BTIG Research decreased their price objective on shares of DexCom from $156.00 to $120.00 and set a "buy" rating for the company in a report on Friday, July 26th. Six research analysts have rated the stock with a hold rating, twelve have issued a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, the company has an average rating of "Moderate Buy" and a consensus target price of $104.59.

DexCom Trading Down 1.8 %

DXCM stock traded down $1.34 during trading on Monday, hitting $72.10. 5,564,987 shares of the company traded hands, compared to its average volume of 3,912,946. The company has a debt-to-equity ratio of 1.00, a quick ratio of 2.48 and a current ratio of 2.82. The company has a 50-day moving average of $70.11 and a 200-day moving average of $97.65. The firm has a market capitalization of $28.67 billion, a PE ratio of 46.69, a P/E/G ratio of 2.26 and a beta of 1.18. DexCom has a 1 year low of $62.34 and a 1 year high of $142.00.

Hedge Funds Weigh In On DexCom

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Migdal Insurance & Financial Holdings Ltd. purchased a new stake in DexCom in the second quarter valued at $25,000. Sachetta LLC boosted its position in DexCom by 255.2% in the 2nd quarter. Sachetta LLC now owns 238 shares of the medical device company's stock valued at $27,000 after buying an additional 171 shares during the period. Crewe Advisors LLC purchased a new position in DexCom in the first quarter valued at $29,000. Riverview Trust Co increased its holdings in DexCom by 100.4% during the 3rd quarter. Riverview Trust Co now owns 463 shares of the medical device company's stock worth $31,000 after purchasing an additional 232 shares during the period. Finally, DT Investment Partners LLC grew its position in shares of DexCom by 492.2% during the second quarter. DT Investment Partners LLC now owns 379 shares of the medical device company's stock worth $43,000 after buying an additional 315 shares in the last quarter. Institutional investors and hedge funds own 97.75% of the company's stock.

Insider Buying and Selling at DexCom

In other DexCom news, EVP Michael Jon Brown sold 652 shares of the company's stock in a transaction that occurred on Wednesday, July 31st. The shares were sold at an average price of $69.55, for a total transaction of $45,346.60. Following the transaction, the executive vice president now owns 66,249 shares in the company, valued at approximately $4,607,617.95. This represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. In other DexCom news, EVP Michael Jon Brown sold 652 shares of the company's stock in a transaction on Wednesday, July 31st. The shares were sold at an average price of $69.55, for a total transaction of $45,346.60. Following the completion of the transaction, the executive vice president now directly owns 66,249 shares in the company, valued at approximately $4,607,617.95. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, COO Jacob Steven Leach sold 746 shares of DexCom stock in a transaction dated Monday, September 9th. The shares were sold at an average price of $69.15, for a total transaction of $51,585.90. Following the completion of the sale, the chief operating officer now owns 264,915 shares in the company, valued at approximately $18,318,872.25. This trade represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 1,824 shares of company stock worth $126,390 over the last three months. Corporate insiders own 0.30% of the company's stock.

About DexCom

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.